62 completed, 15 terminated, 13 unknown, 5 recruiting. 52 Phase 1, 46 Phase 2, 11 Not applicable, 3 Early Phase 1, 1 Phase 3.
Follow Angioimmunoblastic T-cell Lymphoma: new trials by email Literature Review of Angioimmunoblastic T-cell Lymphoma trials Research Report on Angioimmunoblastic T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma azacitidine, abatacept - Lymphoma, T Cell, Peripheral, T-cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 20 | 2026-03-26 | 2026-10-20 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) Cyclophosphamide, Fludarabine, Autologous CCR4 CAR T cells - Relapsed and/or Refractory Mature T Cell Malignancy, Peripheral T-Cell Lymphoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 60 | 2025-09-29 | 2026-10-16 |
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma Fenretinide - T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma | Phase 1 | Recruiting | SciTech Development, Inc. | 46 | 2023-12-18 | 2026-10-05 |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types No interventions need to be specified for this study - Lymphoma, Extranodal Lymphoma | Unknown | Ruijin Hospital | 10000 | 2023-07-01 | 2023-06-18 | |
| Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. Rituximab, Gemcitabine, Dexamethasone - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Not applicable | Unknown | Ou Bai, MD/PHD | 34 | 2023-03-23 | 2023-04-20 |
| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies anti-CD7 CAR-T cells - T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Completed | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 14 | 2022-05-04 | 2025-06-06 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma Anti CD30 CAR-T Cell Injection - Hodgkin Lymphoma, NK/T Cell Lymphoma | Early Phase 1 | Unknown | Zhejiang University | 9 | 2022-02-10 | 2022-01-26 |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Azacitidine, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2022-01-01 | 2022-01-05 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Sintilimab, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 83 | 2021-04-15 | 2021-04-05 |
| Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies anti-TRBC1 CAR-T cell therapy - Peripheral T Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 1 | Suspended | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 9 | 2021-03-31 | 2023-11-29 |
| CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study T cell injection targeting CD7 chimeric antigen receptor - T Lymphoblastic Leukemia/Lymphoma, Extramedullary NK-T-cell Lymphoma, Nasal Type | Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 9 | 2020-11-24 | 2021-01-06 |
| Rituximab Combined With Chidamide and Lenalidomide for r/r AITL Rituximab - Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect | Not applicable | Unknown | Zhejiang Cancer Hospital | 26 | 2020-03-13 | 2021-03-24 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Anti-CD30 CAR T cells - Adult T-Cell Lymphoma/Leukaemia, Anaplastic Large Cell Lymphoma | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 50 | 2019-07-03 | 2019-08-07 |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Chidamide, Cyclophosphamide, Doxorubicin - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2018-12-29 | 2022-04-20 |
Showing 20 of 104. Sign in to see all of them.
Immunoblastic Lymphadenopathy (104) · Lymphoma, Large-Cell, Anaplastic (88) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (74) · Mycosis Fungoides (67) · Sezary Syndrome (67) · Lymphoma, Large B-Cell, Diffuse (65) · Lymphoma, T-Cell, Cutaneous (65) · Leukemia, Lymphocytic, Chronic, B-Cell (63) · Lymphoma, Extranodal NK-T-Cell (63) · Lymphoma, B-Cell, Marginal Zone (62) · Lymphoma, Follicular (60) · Lymphoma, Mantle-Cell (59) · Burkitt Lymphoma (58) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Waldenstrom Macroglobulinemia (56)
Hemic and Lymphatic Diseases (104) · Immune System Diseases (104) · Immunoproliferative Disorders (104) · Lymphadenopathy (104) · Lymphatic Diseases (104) · Lymphoproliferative Disorders (104) · Neoplasms (98) · Neoplasms by Histologic Type (98) · Lymphoma (88) · Hematologic Diseases (81) · Leukemia, Lymphoid (81) · Leukemia (78) · Lymphoma, T-Cell (69) · Lymphoma, B-Cell (68) · Disease Attributes (66)
Peripheral Blood Stem Cell Transplantation (14) · Whole-Body Irradiation (13) · fludarabine phosphate (13) · Cyclophosphamide (12) · Mycophenolic Acid (11) · Etoposide (10) · Cyclosporine (9) · Rituximab (7) · Doxorubicin (6) · Lenalidomide (6) · Vincristine (6) · Azacitidine (5) · Bortezomib (5) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (5) · Prednisone (5)
National Cancer Institute (NCI) (31) · Fred Hutchinson Cancer Center (14) · Mayo Clinic (5) · Case Comprehensive Cancer Center (4) · City of Hope Medical Center (3) · Wake Forest University Health Sciences (3) · Northwestern University (2) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (2) · Roswell Park Cancer Institute (2) · Ruijin Hospital (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · University of Nebraska (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Amir Mortazavi (1)
United States (84) · China (15) · Italy (8) · Canada (6) · Germany (3) · France (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Malaysia (1) · Singapore (1) · Spain (1) · Taiwan (1)
David Maloney (4) · Ajay Gopal (3) · Brenda Sandmaier (3) · Ann Woolfrey (2) · George Chen (2) · Julie M Vose (2) · Paolo Caimi, MD (2) · Ramesh Ramanathan (2) · Samuel Y Ng, M.D. (2) · Aaron R Mangold, M.D. (1) · Adam Petrich, MD (1) · Alex F Herrera (1) · Ali Moiin, MD (1) · Amir Mortazavi, MD (1) · Anas Younes (1)
PMID 32499241, PMID 18698002, PMID 19900571, PMID 22259028, PMID 23256542, PMID 23393050, PMID 24241210, PMID 24352795, PMID 24474568, PMID 26077240, PMID 26213141, PMID 26688485, PMID 26764356, PMID 26943915, PMID 28054442, PMID 28270022, PMID 28314788, PMID 29292843, PMID 29703335, PMID 31617432, PMID 33492438, PMID 35170082, PMID 37276067, PMID 37327113, PMID 39067464, PMID 39528665, PMID 42124356
P30CA015704 (12), P01CA018029 (4), U01CA062491 (4), U01CA076576 (4), U01CA099168 (4), P30CA015083 (3), P30CA016058 (3), U01CA062487 (3), U01CA062505 (3), 2017 (2), P01CA078902 (2), P30CA016672 (2), P30CA033572 (2), P30CA036727 (2), P30CA043703 (2)